Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Arbios Systems Inc (ARBI)

Arbios Systems Inc (ARBI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Arbios Systems Inc

Description:

Arbios Systems, Inc. was incorporated in February 1999, is a Delaware Corporation. The Company seeks to develop, manufacture and market liver assist devices to meet the urgent need for therapy of liver failure. As a development stage company, this engaged solely in the development of new products. The Company has a product under development, the SEPET(tm) Liver Assist Device, which is a blood purification therapy device for patients with liver failure. The Company had a second product candidate, the HepatAssist(tm) Cell-Based Liver Support System, which is a bioartificial liver. The Company entered into an Asset Purchase Agreement with HepaLife Technologies, Inc on October 3, 2008 and sold the HepatAssist(tm) Cell-Based Liver Support System. The liver controls or affects, almost every aspect of metabolism and most physiologic regulatory processes, including protein synthesis, sugar and fat metabolism, blood clotting, the immune system, detoxification of alcohol, chemical toxins, and drugs, and waste removal. If the Company continue to develop SEPET(tm) after the Bankruptcy, the cartridges that would be needed for SEPET(tm) device are expected to be commercially manufactured by NxStage Medical, Inc., and the membrane inside the cartridge are expected to be produced by Membrana GmbH. Additional disposable components, such as tubing connectors, could also be manufactured by third party subcontractors. If developed and commercially released, its SEPET(tm) Liver Assist Device would compete with several other products and technologies that are currently used or are being developed by companies, academic medical centers and research institutions. Other technologies offered by competing companies include the following: Gambro's MARS system and Fresenius's PROMETHEUS system. In order to clinically test, manufacture, and market products for therapeutic use, the Company would have to satisfy mandatory procedures and safety and effectiveness standards established by different regulatory bodies.

Key Statistics

Overview:

Annual Sales, $ 0 K
Annual Net Income, $ 0 K

Growth:

1-Year Return 0.00%
3-Year Return 0.00%
5-Year Return 0.00%

Per-Share Information:

Latest Earnings Date N/A
Dividend Payout Ratio 0.00%

ARBI Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % N/A
Return-on-Assets % N/A
Profit Margin % 0.00%
Debt/Equity N/A
Price/Sales N/A
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share N/A
Interest Coverage N/A
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar